Order results by:
| Issue | Title | |
| Vol 13, No 4 (2020) | Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system | Abstract similar documents |
| T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky | ||
| "... of the evaluation of the shadow cost of the budget, it was 313,878.21 Rub for DALY and 365,060.31 Rub for QALY ..." | ||
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| "... prevented (DALY) and the cost of quality-adjusted life-year saved (QALY) were determined by the suppling ..." | ||
| Vol 11, No 4 (2018) | International experience in determining the cost-effectiveness thresholds | Abstract similar documents |
| T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky | ||
| "... -to-pay threshold (WTP), the threshold value of the incremental cost-effectiveness ratio (ICeR), in europe ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of tixagevimab and cilgavimab combination for COVID-19 therapy | Abstract similar documents |
| M. V. Zhuravleva, V. P. Chulanov, Yu. V. Gagarina, E. A. Shabalina | ||
| "... in additional 0.2657 LIGs or 0.2255 QALYs. The cost of 1 LIG was 213,4 thousand rubles, the cost of 1 QALY ..." | ||
| Vol 5, No 3 (2012) | COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES | Abstract similar documents |
| M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova | ||
| "... , myorelaxants, physical therapy). Measured direct costs at 1-year follow-up. Quality of life was measured ..." | ||
| Vol 16, No 1 (2023) | Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program | Abstract similar documents |
| T. O. Bessonova, P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov, N. Z. Musina | ||
| "... . The incremental cost-effectiveness ratio (ICER) for QALY in the baseline scenario was 3,598,156 rubles, the ICER ..." | ||
| Vol 6, No 4 (2013) | Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа | Abstract similar documents |
| A. Yu. Kulikov, I. V. Novikov | ||
| "... The analysis goal is to determine the cost-effectiveness of liraglutideas add-on to metformin ..." | ||
| Vol 12, No 3 (2019) | Availability and Pharmacoeconomics of Insulin Therapy in Countries with the Largest Number of Diabetics | Abstract PDF (Eng) similar documents |
| S. V. Ponomarenko | ||
| "... segmentation, and the costs for insulin replacement therapy in countries with the largest number of patients ..." | ||
| Vol 17, No 3 (2024) | Review of open libraries for pharmacoeconomic analysis in R environment | Abstract similar documents |
| I. A. Lackman, R. I. Sladkov, V. M. Timiryanova | ||
| "... in the R environment was carried out based on the keywords “health economic”, “DALY”, “QALY” in the CRAN ..." | ||
| Vol 10, No 1 (2017) | THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES | Abstract similar documents |
| N. Z. Musina, V. K. Fedyaeva | ||
| "... This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... and extremely severe COPD (FEV1 <50%, CAT ≥10, mMRC ≥2, with severe symptoms). QALY (quality-adjusted life-year ..." | ||
| Vol 14, No 4 (2021) | Economic burden of chronic viral hepatitis C | Abstract similar documents |
| R. A. Yakhina, I. A. Lakman, D. A. Valishin, R. Kh. Bakhitova | ||
| "... , quality of life adjustment tools (QALY or DALY) were used to estimate the global economic burden. A third ..." | ||
| Vol 8, No 1 (2015) | SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova | ||
| "... Study objective: to perform assessment of the social and economic burden (analysis of the cost ..." | ||
| Vol 9, No 1 (2016) | COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN | Abstract similar documents |
| V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva | ||
| "... according to standard pharmacoeconomic methods: cost-utility analysis (CUA), budget impact analysis (BIA ..." | ||
| Vol 16, No 4 (2023) | Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, S. N. Avdeev, I. N. Barykina, V. O. Lutova, E. A. Popova | ||
| "... horizon equal to life expectancy. The costs of 1 LYG and 1 QALY in the case of benralizumab were 869 ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis | Abstract similar documents |
| A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova | ||
| "... ) with a recalculation into quality-adjusted life-year (QALY). The time horizon of the cost-effectiveness analysis was 2 ..." | ||
| Vol 15, No 1 (2022) | Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation | Abstract similar documents |
| T. O. Bessonova, F. V. Gorkavenko, D. G. Shchurov, Yu. V. Seryapina, O. R. Chetverikova, V. V. Omelyanovskiy, S. N. Krivolapov, N. M. Neminushchiy, A. A. Kalemberg | ||
| "... group compared to the DT group. Incremental cost-effectiveness ratio (ICER) per 1 QALY constituted 2 ..." | ||
| Vol 6, No 2 (2013) | FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS | Abstract similar documents |
| A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure | ||
| "... of type 2 DM therapies liraglutide (Victoza®) was considered as the cost-effective strategy with ICER/QALY ..." | ||
| Vol 5, No 1 (2012) | COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS | Abstract similar documents |
| R. I. Yagudina, I. Yu. Zinchuk, M. M. Litvinenko | ||
| "... Cost of illness is one of the basic methods of pharmacoeconomical estimation and in substance ..." | ||
| Vol 9, No 1 (2016) | COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA | Abstract similar documents |
| G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy | ||
| "... Objective: to perform cost-effectiveness analysis of brentuximab vedotin (BV) in patients ..." | ||
| Vol 6, No 3 (2013) | COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov | ||
| "... contributes to the improvement of approaches to treatment policy of this group of patients. We performed cost ..." | ||
| Vol 17, No 3 (2024) | Economic analysis of implementing Systemic Coronary Risk Estimation (SCORE2) scale and long-term consequences | Abstract similar documents |
| E. O. Kurilovich, A. V. Nikitina, I. V. Sorokovikov | ||
| "... analysis of long-term consequences involved calculating the cost of pharmacotherapy and the costs ..." | ||
| Vol 10, No 1 (2017) | CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS | Abstract similar documents |
| P. V. Мazin, I. V. Sheshunov, N. K. Mazina, E. M. Markova | ||
| "... parameters in this study. The impact on the budget and the “cost-effectiveness” index were also analyzed ..." | ||
| Vol 6, No 2 (2013) | PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION | Abstract similar documents |
| V. A. Chibilyaev, A. Yu. Kulikov, R. I. Yagudina | ||
| "... related to the virus. Use of ART allows to optimize the costs, the value of quality-adjusted life year ..." | ||
| Vol 6, No 3 (2013) | METHODOLOGICAL BASIS OF STANDARD GAMBLE METHOD USAGE IN QUALITY OF LIFE ASSESSMENT IN PHARMACOECONOMIC RESEARCHES | Abstract similar documents |
| R. I. Yagudina, A. Ju. Kulikov, D. T. Ugrekhelidze | ||
| Vol 5, No 2 (2012) | METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES | Abstract similar documents |
| R. I. Yagudina, I. V. Sorokovikov | ||
| "... pharmacoeconomic cost-utility analysis – CUA is at third place by popularity (10% of studies ..." | ||
| Vol 17, No 2 (2024) | Approaches to determining the cost of laboratory tests | Abstract similar documents |
| I. I. Khayrullin, V. V. Omelyanovskiy, R. V. Gostishchev, O. A. Sukhorukikh, S. A. Kovaleva, B. G. Gorodetsky | ||
| "... Background. Determining the cost of laboratory tests is a significant factor in the context ..." | ||
| Vol 9, No 4 (2016) | THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE | Abstract similar documents |
| G. E. Ulrikh, A. V. Rudakova | ||
| "... levo isomer ropivacaine. The aim of this work was to assess the cost of anesthesia levobupivacaine ..." | ||
| Vol 5, No 2 (2012) | THE ANALYSIS OF COST OF ILLNESS OF PREGNANT WOMEN WITH SYPHILIS | Abstract similar documents |
| A. I. Ovod, M. D. Mukovnina | ||
| Vol 8, No 4 (2015) | THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA | Abstract similar documents |
| K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva | ||
| "... breastfeeding. Methods. The cost of providing 100 ml of breast milk (BM) using clinical breast pump and 100 ml ..." | ||
| Vol 12, No 1 (2019) | Individual cost accounting in the management of medical organizations | Abstract similar documents |
| I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali | ||
| "... In the modern economic conditions, the rational planning of costs and the complex process ..." | ||
| Vol 7, No 1 (2014) | ABC END VEN ANALYSYS OF COSTS FOR MEDICINE SAND MEDICAL TREATMENT COSTS PATIENT | Abstract similar documents |
| M. A. Shapovalova, L. R. Koretskaya | ||
| "... of pharmacotherapy and medical services in the department of neurology. An assessment of the costs of hospitalization ..." | ||
| Vol 8, No 4 (2015) | PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER | Abstract similar documents |
| D. A. Zhukov | ||
| "... statistical software was not used). The author presented the method of direct and indirect costs calculation ..." | ||
| Vol 17, No 1 (2024) | Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients | Abstract similar documents |
| О. I. Ivakhnenko, V. V. Ryazhenov, N. A. Falaleeva | ||
| "... direct healthcare costs and incremental cost-effectiveness ratios (ICERs) per 1 life year gained were ..." | ||
| Vol 12, No 3 (2019) | Comorbidity in elderly patients with atrial fibrillation affects the “cost of illness” | Abstract similar documents |
| S. V. Malchikova , N. S. Maksimchuk-Kolobova, M. V. Kazakovtseva | ||
| "... Objective: to analyze whether comorbidity affects the cost of treatment and medical services ..." | ||
| Vol 7, No 3 (2014) | THE ANALYSIS OF METHODOLOGIC CHARACTERISTICS OF RESEARCHES ON SOCIAL AND ECONOMIC BURDEN OF DISEASES IN RUSSIA IN THE FRAMES OF DEVELOPMENT OF STANDARD COST OF ILLNESS METHODOLOGY FOR THE HEALTH TECHNOLOGY ASSESSMENT | Abstract similar documents |
| V. I. Ignatyeva, M. V. Avxentyeva | ||
| "... there are no uninamioulsly accepted methods and approaches for this type of research. The cost of illness method (assessment ..." | ||
| Vol 15, No 4 (2022) | Pharmacoeconomic analysis of antithrombotic therapy in patients with acute coronary syndrome and patients with atrial fibrillation who underwent percutaneous coronary intervention | Abstract similar documents |
| V. А. Ryagina, К. I. Matrenin, D. G. Shchurov, Т. S. Teptsova | ||
| "... -adjusted life year (incremental cost-effectiveness ratio (ICER) per QALY). The result for ticagrelor ..." | ||
| Vol 8, No 2 (2015) | REVIEW OF THE INTERNATIONAL PRACTICE OF COST-SHARING MECHANISM IN NATIONAL HEALTH CARE SYSTEMS | Abstract similar documents |
| Natalia Nikolayevna Sisigina, Vitalii Vladimirovich Omel'yanovskii, Nikolay Alexandrovich Avxentyev | ||
| "... The article gives a review of international experience of using of cost-sharing mechanism ..." | ||
| Vol 10, No 2 (2017) | COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS | Abstract similar documents |
| M. B. Kubaeva, Y. Sh. Guchshina | ||
| "... The aim of our study was to conduct a pharmacoeconomic and cost analysis of the therapeutic use ..." | ||
| Vol 11, No 2 (2018) | Introduction of medical products into healthcare practice and costs reimbursement: European experience | Abstract similar documents |
| V. V. Omelyanovsky, S. S. Otstavnov, N. Z. Musina, V. S. Dombrovskii | ||
| Vol 11, No 4 (2018) | Costs of pharmacotherapy in pediatric patients with community-acquired pneumonia: mathematical and statistical analysis | Abstract similar documents |
| I. A. Narkevich, O. D. Nemyatyh, D. D. Siukaeva, I. V. Pavlushkov, D. O. Ivanov, Ya. V. Panyutina | ||
| "... for the evaluation of pharmacotherapy costs in pediatric inpatients diagnosed with community-acquired pneumonia ..." | ||
| Vol 12, No 4 (2019) | Clinical and economic analysis of drug costs in a general hospital in 2014-2018 | Abstract similar documents |
| A. T. Burbello, A. S. Fedorenko, E. L. Latariya, M. V. Pokladova, K. A. Zagorodnikova | ||
| "... and costs of the purchased drugs as well as their current consumption by various clinical departments ..." | ||
| Vol 17, No 4 (2024) | Development of a classification of anesthetic management methods and protocols for calculating financial costs | Abstract similar documents |
| D. V. Lukyantseva, J. A. Agafonova, V. V. Omelyanovskiy, S. A. Kovaleva, D. V. Fedyaev, I. N. Pasechnik, V. V. Schukin, D. S. Blinov, A. B. Abrosimov | ||
| "... Background. The costs of anesthetic support represent a significant and essential component ..." | ||
| Vol 17, No 4 (2024) | Standardized methodology for calculating the cost of medical care funded by government sources | Abstract similar documents |
| M. A. Sdvizhkova, S. A. Kovaleva, D. V. Fedyaev, V. V. Omelyanovskiy | ||
| "... . Efficient allocation of financial resources is becoming a priority. Calculating the cost of MC is considered ..." | ||
| Vol 8, No 2 (2015) | PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS | Abstract similar documents |
| Anton Alexandrovich Kasatkin | ||
| "... of analysis of the cost of the disease, including the payment of medical costs for medical services, medicines ..." | ||
| Vol 13, No 4 (2020) | The social-economic burden of spinal muscular atrophy in Russia | Abstract similar documents |
| A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina | ||
| "... (medical, social etc.) throughout their life and the cost of the care has never been calculated in Russia ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER | Abstract similar documents |
| A. U. Kulikov | ||
| Vol 6, No 4 (2013) | Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis | Abstract similar documents |
| R. I. Yagudina, M. M. Murashko | ||
| "... and Sterofundin drugs were compared during the analysis. A cost analysis, cost-effectiveness analysis, budget ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic analysis of the application of strong opioids for the treatment of chronic pain syndrome in patients with pancreatic cancer | Abstract similar documents |
| O. P. Bobrova, S. K. Zyryanov, N. A. Shnayder, M. M. Petrova | ||
| "... on the analysis of its cost and effectiveness in patients with chronic pain syndrome in pancreatic cancer ..." | ||
| Vol 5, No 2 (2012) | COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS | Abstract similar documents |
| A. V. Rudakova | ||
| 1 - 50 of 236 Items | 1 2 3 4 5 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
